| Budget Amount *help |
¥27,170,000 (Direct Cost: ¥20,900,000、Indirect Cost: ¥6,270,000)
Fiscal Year 2018: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2017: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2016: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Outline of Final Research Achievements |
Quantitative data of 4846 proteins and 16267 phosphorylation sites were obtained from 35 esophageal squamous cell carcinoma cell lines. Phosphoproteome had high specificity among cells, and even in part of cells in which EGFR and ERBB2 gene amplification were not observed, kinase activation was observed. Pharmacoproteomics data integrating kinase activity of individual cells and sensitivity information of 439 inhibitors were prepared, and optimal combination information of molecular target candidates and drugs was obtained. It is suggested that stratification of patients is important for development of new treatment methods, and it is expected that our data will serve as basic data for drug candidate selection from clinical specimen data in the future.
|
